Wolff Wiese Magana LLC lowered its stake in shares of Lantern Pharma Inc. (NASDAQ:LTRN – Get Rating) by 12.7% during the second quarter, according to its most recent Form 13F filing with the SEC. The fund owned 31,575 shares of the company’s stock after selling 4,580 shares during the period. Wolff Wiese Magana LLC owned 0.29% of Lantern Pharma worth $180,000 at the end of the most recent quarter.
A number of other institutional investors and hedge funds also recently added to or reduced their stakes in LTRN. Advisor Group Holdings Inc. boosted its stake in Lantern Pharma by 92.5% during the fourth quarter. Advisor Group Holdings Inc. now owns 5,331 shares of the company’s stock worth $43,000 after buying an additional 2,561 shares during the last quarter. JPMorgan Chase & Co. raised its position in Lantern Pharma by 52.7% in the first quarter. JPMorgan Chase & Co. now owns 8,018 shares of the company’s stock valued at $57,000 after purchasing an additional 2,768 shares during the period. Renaissance Technologies LLC purchased a new stake in Lantern Pharma in the first quarter valued at $77,000. Envestnet Asset Management Inc. purchased a new stake in Lantern Pharma in the fourth quarter valued at $84,000. Finally, State Street Corp raised its position in Lantern Pharma by 8.5% in the first quarter. State Street Corp now owns 27,752 shares of the company’s stock valued at $198,000 after purchasing an additional 2,185 shares during the period. Institutional investors and hedge funds own 13.10% of the company’s stock.
Lantern Pharma Price Performance
NASDAQ:LTRN traded down $0.07 on Friday, reaching $4.68. The company’s stock had a trading volume of 32 shares, compared to its average volume of 17,682. Lantern Pharma Inc. has a 12-month low of $4.67 and a 12-month high of $12.50. The stock has a 50 day moving average price of $5.39 and a 200 day moving average price of $5.85.
Lantern Pharma Company Profile
Lantern Pharma Inc, a clinical stage biotechnology company, focuses on artificial intelligence, machine learning, and genomic data to streamline the drug development process. Its advanced drug candidate is LP-100, which is in phase II clinical trials to treat metastatic, castration-resistant, and prostate cancer.
- Get a free copy of the StockNews.com research report on Lantern Pharma (LTRN)
- Why Does Tesla Stock Remain Resilient?
- 2 Semiconductor Stocks To Watch For Reversals
- Is Costco’s Post-Earnings Price Weakness A Good Time To Buy?
- Will Crowdstrike Get A Boost From Increased EPS Guidance?
- Are Layoffs At A Small-Cap Tech A Bellwether For Housing Stocks?
Receive News & Ratings for Lantern Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Lantern Pharma and related companies with MarketBeat.com's FREE daily email newsletter.